OncoSec Medical (NASDAQ:ONCS) had its target price cut by Piper Jaffray Companies from $5.00 to $3.00 in a research report sent to investors on Tuesday morning, The Fly reports. They currently have an overweight rating on the biotechnology company’s stock.
Other research analysts have also recently issued reports about the company. HC Wainwright set a $4.00 price objective on OncoSec Medical and gave the stock a buy rating in a research report on Tuesday, July 31st. Dawson James reaffirmed a buy rating on shares of OncoSec Medical in a research report on Monday, July 16th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $4.00.
NASDAQ:ONCS opened at $0.97 on Tuesday. OncoSec Medical has a 1 year low of $0.68 and a 1 year high of $2.95. The stock has a market capitalization of $111.32 million, a price-to-earnings ratio of -0.93 and a beta of 2.28.
OncoSec Medical Company Profile
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.